Your browser doesn't support javascript.
Novel biomarkers for potential risk stratification of drug induced liver injury (DILI): A narrative perspective on current trends.
Medicine (Baltimore) ; 98(50): e18322, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31852121


Drug induced liver injury (DILI) is an increasing cause of acute liver injury especially with increasing need for pharmacotherapy of widening comorbidities amongst our ever-aging population. Uncertainty however remains regarding both acceptable and widely agreeable diagnostic algorithms as well a clear understanding of mechanistic insights that most accurately underpins it. In this review, we have explored the potential role of emerging novel markers of DILI and how they could possibly be integrated into clinical care of patients.


We explored PUBMED and all other relevant databases for scientific studies that explored potential utility of novel biomarkers of DILI, and subsequently carried out a narrative synthesis of this data. As this is a narrative review with no recourse to patient identifiable information, no ethics committee's approval was sought or required.


Novel biomarkers such as microRNA-122 (miR-122) profiles, high mobility group box-1 (HMGB1), glutamate dehydrogenase (GLDH), and cytokeratin-18 (K-18), amongst others do have the potential for reducing diagnostic uncertainties associated with DILI.


With the increasing validation of some of the novel liver biomarkers such as K-18, mir-122, HMGB-1, and GLDH, there is the potential for improvement in the diagnostic uncertainty commonly associated with cases of DILI.





Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Medição de Risco / Proteína HMGB1 / MicroRNAs / Queratina-18 / Doença Hepática Induzida por Substâncias e Drogas / Glutamato Desidrogenase Aspecto clínico: Diagnóstico / Etiologia Limite: Humanos Idioma: Inglês Revista: Medicine (Baltimore) Ano de publicação: 2019 Tipo de documento: Artigo